Collaboration on the role of microRNAs in neurodegenerative disease
Dutch biopharma InteRNA Technologies has entered into a collaborative agreement with two partners from the Neuroallianz Consortium - UCB Pharma and the Rheinische Friedrich-Wilhelms-University Bonn - to support the investigation of microRNAs (miRNAs) in neurodegenerative diseases.
InteRNA, working closely with Jeroen Pasterkamp, Professor of Translational Neuroscience at UMC Utrecht, will apply its platform for multiparametric, high-throughput functional screening assays to identify and validate the biological role of individual miRNAs and novel therapeutic targets for neurodegenerative disease.
The collaboration forms an integral part of the Neuroallianz project ‘miRNAs in Neurodegenerative Diseases’ partnered by the University of Bonn and UCB and funded by the Federal Ministry for Education and Research (BMBF) in Germany.
According to Roel Schaapveld, CEO of InteRNA Technologies, “The selection of InteRNA to support this program validates the uniqueness of our platform and confirms its potential use outside oncology.”
Though InteRNA is building its own pipeline of miRNA drug candidates for cancer, it has shown the validity of its platform for discovery and validation of miRNAs drug candidates and their mode of action for other disease indications.
Blood-based biomarker can detect sleep deprivation
The biomarker detected whether individuals had been awake for 24 hours with a 99.2% probability...
Epigenetic signature helps to diagnose rare breast tumour
The current way of diagnosing phyllodes tumours is to analyse their cellular features under a...
New instrument measures cardiovascular disease biomarkers
CVD-21 enables a 'liquid cardiovascular biopsy' for quantification of multiple...
